Characterization, Mechanism of Action and Optimization of Activity of a Novel Peptide-peptoid Hybrid Against Bacterial Pathogens Involved in Canine Skin Infections

Overview

Journal Sci Rep

Specialty Science

Date 2019 Mar 8

PMID 30842436

Citations 16

Authors

Ines Greco

Agnete Plahn Emborg

Bimal Jana

Natalia Molchanova

Alberto Oddo

Peter Damborg

Luca Guardabassi

Paul R Hansen

Affiliations

Soon will be listed here.

Abstract

Integumentary infections like pyoderma represent the main reason for antimicrobial prescription in dogs. Staphylococcus pseudintermedius and Pseudomonas aeruginosa are frequently identified in these infections, and both bacteria are challenging to combat due to resistance. To avoid use of important human antibiotics for treatment of animal infections there is a pressing need for novel narrow-spectrum antimicrobial agents in veterinary medicine. Herein, we characterize the in vitro activity of the novel peptide-peptoid hybrid B1 against canine isolates of S. pseudintermedius and P. aeruginosa. B1 showed potent minimum inhibitory concentrations (MICs) against canine S. pseudintermedius and P. aeruginosa isolates as well rapid killing kinetics. B1 was found to disrupt the membrane integrity and affect cell-wall synthesis in methicillin-resistant S. pseudintermedius (MRSP). We generated 28 analogues of B1, showing comparable haemolysis and MICs against MRSP and P. aeruginosa. The most active analogues (23, 26) and B1 were tested against a collection of clinical isolates from canine, of which only B1 showed potent activity. Our best compound 26, displayed activity against P. aeruginosa and S. pseudintermedius, but not the closely related S. aureus. This work shows that design of target-specific veterinary antimicrobial agents is possible, even species within a genus, and deserves further exploration.

Citing Articles

Ellagic Acid Potentiates the Inhibitory Effects of Fluconazole Against .

Mendes A, Campos C, Pereira-Filho J, Pereira A, Reis G, Araujo A Antibiotics (Basel). 2025; 13(12.

PMID: 39766564 PMC: 11672414. DOI: 10.3390/antibiotics13121174.

Discovery of a Peptoid-Based Nanoparticle Platform for Therapeutic mRNA Delivery via Diverse Library Clustering and Structural Parametrization.

Webster E, Peck N, Echeverri J, Gholizadeh S, Tang W, Woo R ACS Nano. 2024; 18(33):22181-22193.

PMID: 39105751 PMC: 11342374. DOI: 10.1021/acsnano.4c05513.

Antimicrobial Strategies Proposed for the Treatment of and Other Dermato-Pathogenic spp. in Companion Animals: A Narrative Review.

Stefanetti V, Passamonti F, Rampacci E Vet Sci. 2024; 11(7).

PMID: 39057995 PMC: 11281426. DOI: 10.3390/vetsci11070311.

Fmoc Solid-Phase Peptide Synthesis.

Hansen P, Oddo A Methods Mol Biol. 2024; 2821:33-55.

PMID: 38997478 DOI: 10.1007/978-1-0716-3914-6_3.

Design of a novel analogue peptide with potent antibiofilm activities against Staphylococcus aureus based upon a sapecin B-derived peptide.

Akhash N, Farajzadeh Sheikh A, Farshadzadeh Z Sci Rep. 2024; 14(1):2256.

PMID: 38278972 PMC: 10817945. DOI: 10.1038/s41598-024-52721-0.

References

Runti G, Benincasa M, Giuffrida G, Devescovi G, Venturi V, Gennaro R . The Mechanism of Killing by the Proline-Rich Peptide Bac7(1-35) against Clinical Strains of Pseudomonas aeruginosa Differs from That against Other Gram-Negative Bacteria. Antimicrob Agents Chemother. 2017; 61(4). PMC: 5365664. DOI: 10.1128/AAC.01660-16. View

Cabassi C, Taddei S, Cavirani S, Baroni M, Sansoni P, Romani A . Broad-spectrum activity of a novel antibiotic peptide against multidrug-resistant veterinary isolates. Vet J. 2013; 198(2):534-7. DOI: 10.1016/j.tvjl.2013.08.020. View

Munk J, Ritz C, Fliedner F, Frimodt-Moller N, Hansen P . Novel method to identify the optimal antimicrobial peptide in a combination matrix, using anoplin as an example. Antimicrob Agents Chemother. 2013; 58(2):1063-70. PMC: 3910807. DOI: 10.1128/AAC.02369-13. View

Collignon P . Antibiotic resistance: are we all doomed?. Intern Med J. 2015; 45(11):1109-15. DOI: 10.1111/imj.12902. View

Memariani H, Shahbazzadeh D, Sabatier J, Memariani M, KarbalaeiMahdi A, Pooshang Bagheri K . Mechanism of action and in vitro activity of short hybrid antimicrobial peptide PV3 against Pseudomonas aeruginosa. Biochem Biophys Res Commun. 2016; 479(1):103-8. DOI: 10.1016/j.bbrc.2016.09.045. View

Galperine T, Cazorla C, Blanchard E, Boineau F, Ragnaud J, Neau D . Streptococcus canis infections in humans: retrospective study of 54 patients. J Infect. 2007; 55(1):23-6. DOI: 10.1016/j.jinf.2006.12.013. View

Santoro D, Maddox C . Canine antimicrobial peptides are effective against resistant bacteria and yeasts. Vet Dermatol. 2013; 25(1):35-e12. DOI: 10.1111/vde.12091. View

Lee J, Kang D, Choi J, Huang W, Wadman M, Barron A . Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids. Bioorg Med Chem Lett. 2017; 28(2):170-173. DOI: 10.1016/j.bmcl.2017.11.034. View

Greco I, Hummel B, Vasir J, Watts J, Koch J, Hansen J . In Vitro ADME Properties of Two Novel Antimicrobial Peptoid-Based Compounds as Potential Agents against Canine Pyoderma. Molecules. 2018; 23(3). PMC: 6017477. DOI: 10.3390/molecules23030630. View

10.

Subbalakshmi C, Sitaram N . Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett. 1998; 160(1):91-6. DOI: 10.1111/j.1574-6968.1998.tb12896.x. View

11.

Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U . Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science. 2010; 328(5982):1168-72. DOI: 10.1126/science.1185723. View

12.

Gottschalk S, Ifrah D, Lerche S, Gottlieb C, Cohn M, Hiasa H . The antimicrobial lysine-peptoid hybrid LP5 inhibits DNA replication and induces the SOS response in Staphylococcus aureus. BMC Microbiol. 2013; 13:192. PMC: 3751284. DOI: 10.1186/1471-2180-13-192. View

13.

Grieco P, Carotenuto A, Auriemma L, Saviello M, Campiglia P, Gomez-Monterrey I . The effect of d-amino acid substitution on the selectivity of temporin L towards target cells: identification of a potent anti-Candida peptide. Biochim Biophys Acta. 2012; 1828(2):652-60. DOI: 10.1016/j.bbamem.2012.08.027. View

14.

Jahnsen R, Sandberg-Schaal A, Vissing K, Nielsen H, Frimodt-Moller N, Franzyk H . Tailoring cytotoxicity of antimicrobial peptidomimetics with high activity against multidrug-resistant Escherichia coli. J Med Chem. 2014; 57(7):2864-73. DOI: 10.1021/jm401335p. View

15.

Goodwin J, McCamley R . Otitis externa associated with Ps aeruginosa infection. Vet Rec. 1978; 103(15):343. DOI: 10.1136/vr.103.15.343-a. View

16.

Gomez-Sanz E, Torres C, Lozano C, Zarazaga M . High diversity of Staphylococcus aureus and Staphylococcus pseudintermedius lineages and toxigenic traits in healthy pet-owning household members. Underestimating normal household contact?. Comp Immunol Microbiol Infect Dis. 2012; 36(1):83-94. DOI: 10.1016/j.cimid.2012.10.001. View

17.

Mercer D, ONeil D . Peptides as the next generation of anti-infectives. Future Med Chem. 2013; 5(3):315-37. DOI: 10.4155/fmc.12.213. View

18.

Blondeau J, Borsos S, Blondeau L, Blondeau B . In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat. Vet Microbiol. 2011; 155(2-4):284-90. DOI: 10.1016/j.vetmic.2011.08.015. View

19.

Eckert R, Qi F, Yarbrough D, He J, Anderson M, Shi W . Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp. Antimicrob Agents Chemother. 2006; 50(4):1480-8. PMC: 1426969. DOI: 10.1128/AAC.50.4.1480-1488.2006. View

20.

Fosgerau K, Hoffmann T . Peptide therapeutics: current status and future directions. Drug Discov Today. 2014; 20(1):122-8. DOI: 10.1016/j.drudis.2014.10.003. View